BioSpace News Archive

Intrarosa ® is now available in Canada and offers a new treatment option for Canadian physicians and their patients with postmenopausal vulvovaginal atrophy (VVA).

Juvena Therapeutics , Inc. announced today the hiring of four senior leaders with significant industry experience in both small and large pharmaceutical and biotech companies.

Fennec Pharmaceuticals Inc. today announced that the National Comprehensive Cancer Network® (NCCN) has updated its clinical practice guidelines for Adolescent and Young Adult (AYA) Oncology to include PEDMARK® (sodium thiosulfate injection) to help reduce the risk of ototoxicity (hearing loss) associated with cisplatin use in pediatric patients with localized, non-metastatic solid tumors.

Alterity Therapeutics today announced the Company’s Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrollment in Italy.

Dante Genomics, a global leader in genomics and precision medicine, announced today that their laboratory in Dubai, which serves as a global hub for the Eastern Hemisphere, has received Medical Laboratory accreditation ISO 15189 to bring clinical whole genome sequencing to hospitals and physicians in the Middle East, Asia and Africa.

Apyx Medical Corporation (NASDAQ: APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the launch of its latest-generation Renuvion generator, the Apyx One Console, in the United States.

The Foundation Fighting Blindness will host the free in-person PRPH2 and Associated Retinal Diseases Workshop on March 29–31, 2023, at the Hilton La Jolla Torrey Pines in San Diego, CA.

Annovis Bio, Inc. today provided a patient enrollment update for the Company’s ongoing Phase 3 study of buntanetap for the treatment of Parkinson’s disease (“PD”).

Precision Neuroscience Corporation, the only brain–computer interface company developing implants that are designed to be high-resolution, minimally invasive, and reversible, announced a $41 million Series B funding round led by Forepont Capital Partners.

Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it has successfully completed the acquisition of the U.S. rights for FYCOMPA® (perampanel) CIII, from Eisai Co., Ltd, (“Eisai”).